Trials

Comparing remimazolam and propofol for starting anesthesia in minimally invasive lung surgery

Updated

Abstract

A total of 172 patients will be evaluated for hypotension within 20 minutes after anesthesia induction using either remimazolam or propofol.

  • Intraoperative hypotension is linked to increased risks of postoperative complications such as myocardial injury and acute kidney injury.
  • More than half of intraoperative hypotension incidents occur immediately after the induction of general anesthesia.
  • Propofol, commonly used for anesthesia induction, can cause hemodynamic instability, leading to adverse outcomes.
  • Remimazolam, an ultra-short-acting intravenous sedative-hypnotic, may offer more stable hemodynamics compared to propofol.
  • Previous studies suggest remimazolam is associated with a lower incidence of hypotension than propofol.

Simplified

Key numbers

172
Sample Size
Patients aged 45 to 65 years undergoing thoracoscopic surgery.
50%
Incidence of Hypotension
Estimated incidence of hypotension based on previous studies.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Declarations. Ethics approval and consent to participate {24}: The study protocol has been approved by the Ethics Committee of West China Hospital of Sichuan University (Ethics Committee No. 2023(2258)) and registered at chictr.org.cn (ID: ChiCTR2400085556) on June 12, 2024. All patients will provide written informed consent before the start of any protocol‐specified procedures or assessments. The patients can withdraw from the trial at any time. The results of the study will be presented at relevant conferences and submitted to international peer‐reviewed journals. Consent for publication {32}: Not applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request. Competing interests {28}: The authors declare that they have no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free